SOURCE: Amarillo Biosciences, Inc.

August 02, 2007 10:24 ET

Amarillo Biosciences Plans a Human Influenza Clinical Trial in Perth, Australia

AMARILLO, TX--(Marketwire - August 2, 2007) - Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced that it has agreed to conduct human influenza research with Dr. Manfred Beilharz, Chair of Microbiology and Immunology, School of Biomedical, Bimolecular and Chemical Sciences, The University of Western Australia. "We have been collaborating with Dr. Beilharz for more than 10 years," said Dr. Cummins, CEO of ABI. "During that time, Dr. Beilharz has published 10 scientific papers or abstracts on the low-dose, oral use of interferon. We are pleased to extend our research collaboration with Dr. Beilharz. His exciting discoveries regarding how oral interferon can protect against influenza are critically important as the world prepares for the next influenza pandemic," said Dr. Joseph Cummins.

Recent publications from Freiburg, Germany by scientists (Grimm, et al. Proceeding National Academy of Sciences, April 2007) and from (Tumpey, et al. the Centers of Disease Control (CDC) and Prevention in Atlanta, J Virology, July 2007) report that a single dose of interferon placed in the nose of mice reduces mortality from 50% to 0% (CDC) or 100% to 0% (Germany) in H5N1 ("Bird flu") influenza (CDC) or unique virulent influenza (Germany) infections.

"We published earlier in 2007 that interferon in the mouth protects mice against fatal influenza," said Professor Beilharz. "We used a concentration of interferon similar to that used by CDC and also reported that a dosage 100 times less was also protective against fatal influenza infection in mice. Our goal from new animal research is to determine the optimal dose and timing of administration of oral interferon so we can more carefully design human clinical trials. These human clinical trials will not only address the influenza issue, but will also address a new approach to winter colds and flu-like conditions," said Professor Beilharz.

Perth is a city in Western Australia with 2 million residents. The clinical study will be conducted there in childcare workers, school teachers and hospital workers who will be naturally exposed to infections of influenza and other respiratory pathogens. Some subjects will take placebo daily during the next "flu season" and others will take oral interferon at the dosages covered by ABI's issued U.S. patents. Besides ABI's patented dose formulation, two of ABI's issued U.S. patents have claims which directly apply to the low-dose oral use of interferon for influenza.

About Amarillo Biosciences, Inc.

Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 12% of Amarillo Biosciences shares and has provided over $17.9 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including Sjogren's syndrome, Behcet's disease, and opportunistic infections in patients who are HIV positive. In its 23-year history, ABI has invested nearly $38 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available on the ABI web site at http://www.amarbio.com/.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" of the Company's Form 10-KSB for the year ended December 31, 2006.

Contact Information

  • Investor Relations:
    Philippe Niemetz
    PAN Consultants, Ltd.
    e-mail: Email Contact
    Tel: 800-477-7570; 212-344-6464
    Fax: 212-618-1276

    Joseph M. Cummins, DVM, PhD
    Amarillo Biosciences, Inc.
    e-mail: Email Contact
    Tel: 806-376-1741 x 13
    Fax: 806-376-9301